ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
Rhea-AI Summary
ANI Pharmaceuticals (Nasdaq: ANIP) will release its first quarter 2026 financial results on Friday, May 8, 2026, prior to market open.
A webcast and conference call with CEO Nikhil Lalwani, CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz will discuss the results; a replay will remain accessible for up to one year. Webcast links are on the Investors > Events & Presentations page.
Positive
- None.
Negative
- None.
News Market Reaction – ANIP
In the Apr 24 session, ANIP gained 0.74%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 27 | Earnings results | Positive | -4.2% | Record Q4 and 2025 results with reaffirmed 2026 revenue and EBITDA guidance. |
| Feb 13 | Earnings call notice | Neutral | +0.9% | Announcement of Q4 and full-year 2025 results release and conference call. |
| Nov 07 | Earnings results | Positive | +0.2% | Record Q3 2025 results and raised 2025 revenue and EBITDA guidance. |
| Oct 24 | Earnings call notice | Neutral | -0.7% | Scheduling of Q3 2025 results release and investor conference call. |
| Aug 08 | Earnings results | Positive | +18.1% | Record Q2 2025 results and raised full-year 2025 revenue and EBITDA guidance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-related news has generally been positive operationally, with most events showing aligned price reactions, though one record-results release saw a negative move despite strong metrics. Pre-announcement call notices have historically produced modest, mixed price changes.
Over the past few quarters, ANI has reported a series of record financial results, including record Q2 2025, Q3 2025 and Q4 2025 revenues, repeated guidance raises, and reaffirmed targets for >$1B 2026 revenue and adjusted EBITDA of $275M–$290M. Alongside these, it regularly issues press releases scheduling earnings calls. Today’s announcement fits that pattern as a standard notice for the upcoming Q1 2026 results discussion.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8, 2026, prior to the market open.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results.
To view the webcast, please click here. Links to access the webcast and conference call will also be available on the “Events & Presentations” page of the Company’s website at https://www.anipharmaceuticals.com, under the “Investors” section. A replay of the event will remain accessible for up to one year.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.
Investor Relations:
Courtney Mogerley, Argot Partners
T: 646-368-8014
E: ani@argotpartners.com
Media Relations:
Argot Partners
T: 212-600-1494
E: ani@argotpartners.com
